TABLE 2.
Distribution of serogroups/types of noninvasive S. pneumoniae collected during 2009 to 2012 in the United States
| Serogroup/type(s)a | No. (%) by yr |
No. (%) for all yrs | |||
|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | ||
| PCV7 | 25 (4.6) | 38 (5.5) | 47 (5.0) | 37 (5.0) | 147 (5.0) |
| 19F | 15 (2.7) | 24 (3.5) | 31 (3.3) | 25 (3.4) | 95 (3.2) |
| 9V/9A | 3 (0.5) | 0 (0.0) | 6 (0.6) | 2 (0.3) | 11 (0.4) |
| 23F | 2 (0.4) | 4 (0.6) | 2 (0.2) | 3 (0.4) | 11 (0.4) |
| 6B | 2 (0.4) | 2 (0.3) | 4 (0.4) | 2 (0.3) | 10 (0.3) |
| 18 (18A/18B/18C/18F) | 3 (0.5) | 2 (0.3) | 0 (0.0) | 2 (0.3) | 7 (0.2) |
| 14 | 0 (0.0) | 4 (0.6) | 1 (0.1) | 2 (0.3) | 7 (0.2) |
| 4 | 0 (0.0) | 2 (0.3) | 3 (0.3) | 1 (0.1) | 6 (0.2) |
| PCV13* | 195 (35.5) | 232 (33.7) | 319 (33.8) | 210 (28.2) | 956 (32.7) |
| 19A | 88 (16.0) | 109 (15.8) | 161 (17.1) | 91 (12.2) | 449 (15.3) |
| 3 | 50 (9.1) | 60 (8.7) | 84 (8.9) | 64 (8.6) | 258 (8.8) |
| 7F* | 21 (3.8) | 22 (3.2) | 24 (2.5) | 13 (1.7) | 80 (2.7) |
| 6A* | 11 (2.0) | 3 (0.4) | 3 (0.3) | 5 (0.7) | 22 (0.8) |
| 1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| 5 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| PPSV23-nonPCV13 | 134 (24.4) | 172 (25.0) | 229 (24.3) | 197 (26.4) | 732 (25.0) |
| 11A/11D | 34 (6.2) | 41 (6.0) | 49 (5.2) | 44 (5.9) | 168 (5.7) |
| 22A/22F | 31 (5.6) | 36 (5.2) | 49 (5.2) | 35 (4.7) | 151 (5.2) |
| 15B/15C* | 15 (2.7) | 36 (5.2) | 47 (5.0) | 47 (6.3) | 145 (5.0) |
| 9N/9L | 12 (2.2) | 22 (3.2) | 26 (2.8) | 21 (2.8) | 81 (2.8) |
| 17F | 14 (2.6) | 11 (1.6) | 15 (1.6) | 11 (1.5) | 51 (1.7) |
| 10A | 13 (2.4) | 6 (0.9) | 20 (2.1) | 11 (1.5) | 50 (1.7) |
| 33F/33A/37 | 7 (1.3) | 8 (1.2) | 14 (1.5) | 12 (1.6) | 41 (1.4) |
| 20 | 2 (0.4) | 6 (0.9) | 3 (0.3) | 9 (1.2) | 20 (0.7) |
| 8 | 4 (0.7) | 4 (0.6) | 5 (0.5) | 6 (0.8) | 19 (0.6) |
| 12F/12A/44/46 | 2 (0.4) | 2 (0.3) | 1 (0.1) | 1 (0.1) | 6 (0.2) |
| Nonvaccine* | 207 (37.7) | 271 (39.4) | 374 (39.6) | 324 (43.4) | 1,176 (40.2) |
| 6C/6D | 45 (8.2) | 40 (5.8) | 64 (6.8) | 54 (7.2) | 203 (6.9) |
| 35B* | 20 (3.6) | 45 (6.5) | 75 (7.9) | 61 (8.2) | 201 (6.9) |
| 23A | 31 (5.6) | 32 (4.7) | 54 (5.7) | 46 (6.2) | 163 (5.6) |
| 15A/15F | 30 (5.5) | 40 (5.8) | 44 (4.7) | 34 (4.6) | 148 (5.1) |
| 23B | 22 (4.0) | 22 (3.2) | 37 (3.9) | 43 (5.8) | 124 (4.2) |
| 16F | 15 (2.7) | 23 (3.3) | 22 (2.3) | 16 (2.1) | 76 (2.6) |
| 31 | 13 (2.4) | 18 (2.6) | 23 (2.4) | 20 (2.7) | 74 (2.5) |
| 34 | 6 (1.1) | 17 (2.5) | 12 (1.3) | 11 (1.5) | 46 (1.6) |
| 35F/47F | 10 (1.8) | 10 (1.5) | 11 (1.2) | 8 (1.1) | 39 (1.3) |
| 7C/7B/40 | 5 (0.9) | 12 (1.7) | 10 (1.1) | 7 (0.9) | 34 (1.2) |
| 13 | 3 (0.5) | 4 (0.6) | 3 (0.3) | 8 (1.1) | 18 (0.6) |
| 21 | 3 (0.5) | 2 (0.3) | 6 (0.6) | 7 (0.9) | 18 (0.6) |
| 38/25F/25A | 1 (0.2) | 2 (0.3) | 9 (1.0) | 5 (0.7) | 17 (0.6) |
| Other | 3 (0.5) | 4 (0.6) | 4 (0.4) | 4 (0.5) | 15 (0.5) |
| Nontypeable | 13 (2.4) | 13 (1.9) | 22 (2.3) | 15 (2.0) | 63 (2.2) |
| All | 549 (100.0) | 688 (100.0) | 944 (100.0) | 746 (100.0) | 2,927 (100.0) |
a
Differences in serotype prevalence rates over time were assessed by calculating the P values by the chi-square test for trends using Epi Info, version 7.1.1.14. *, calculated P values were <0.05 and were considered statistically significant. “Nonvaccine” indicates those strains not present in the three vaccines available in the United States.